Moreover, lapatinib (a Her2 inhibitor) has been shown to be useful in treatment when combined with other agents in breast cancer models of the basal phenotype (Liu et al., 2011), therefore the association of this molecular subtype with Her2 signaling pathway is not entirely new. This evidence concerns the gene ERBB2 and breast carcinoma.